drugset / Trial / NCT00151684

Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men

NCT00151684

Phase 2 Completed 25 enrolled Rijnstate Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia. Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.

Timeline

Start
2004-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Unknown 900 mg